TrialSignal
Clinical trial intelligence report
A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01424163
Status
COMPLETED
Phase
PHASE1
Sponsor
Knopp Biosciences
Executive brief
Investment-Ready Snapshot
This is a single and multiple dose, open-label study to evaluate the pharmacokinetics (PK), safety, and tolerability of dexpramipexole administered orally to adult Japanese and Caucasian healthy subjects.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01424163
Indication
Amyotrophic Lateral Sclerosis
Modality
small molecule
Target
Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose
Intervention
Single dose reduced, Single dose standard, Multiple Dose, Multiple Dose
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.